While initial clinical trials have reported encouraging average weight loss results, they have also highlighted possible common side effects similar to those seen with GLP-1 agonists, such as: Currently, Retatrutide is not legal for sale or prescription in the UK
If retatrutide follows the same pattern, we would expect an Eli Lilly regulatory filing in late 2026, MHRA approval in late 2027 to mid-2028, and NHS access through NICE from 2029 at the earliest
This flexibility is similar to Noom and some newer programs, but differs from plans with strict meal guidelines or proprietary products
Diarrhea and Loose Stools Paradoxically, some patients experience diarrhea from weight loss drugs rather than constipation
CrossRef The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis Junjie Lin, Rongtao Yang, Jiacheng Zhuang, Wenbo Zhang, Qiang Tong, Jiahui Liu, Ye Kang, Yuan Yuan Journal of Ovarian Research.2026;[Epub] CrossRef Hypothalamus-liver talks: whispers in the language of metabolism Vitor Ferreira, Iara Fernndez-Gonzlez, Jane Jose Vattathara, Amanda Rodrguez-Daz, Paola Fernndez-Sanmartn, Carlos Diguez Reviews in Endocrine and Metabolic Disorders.2026
